Data from CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer

Abstract

<div>Abstract<p>Myeloid-derived suppressor cells (MDSC) are an immunosuppressive population of immature myeloid cells found in advanced-stage cancer patients and mouse tumor models. Production of inducible nitric oxide synthase (iNOS) and arginase, as well as other suppressive mechanisms, allows MDSCs to suppress T-cell–mediated tumor clearance and foster tumor progression. Using an unbiased global gene expression approach in conditional p120-catenin knockout mice (<i>L2-cre;p120ctn<sup>f/f</sup></i>), a model of oral–esophageal cancer, we have identified CD38 as playing a vital role in MDSC biology, previously unknown. CD38 belongs to the ADP-ribosyl cyclase family and possesses both ectoenzyme and receptor functions. It has been described to function in lymphoid and early myeloid cell differentiation, cell activation, and neutrophil chemotaxis. We find that CD38 expression in MDSCs is evident in other mouse tumor models of esophageal carcinogenesis, and CD38<sup>high</sup> MDSCs are more immature than MDSCs lacking CD38 expression, suggesting a potential role for CD38 in the maturation halt found in MDSC populations. CD38<sup>high</sup> MDSCs also possess a greater capacity to suppress activated T cells, and promote tumor growth to a greater degree than CD38<sup>low</sup> MDSCs, likely as a result of increased iNOS production. In addition, we have identified novel tumor–derived factors, specifically IL6, IGFBP3, and CXCL16, which induce CD38 expression by MDSCs <i>ex vivo</i>. Finally, we have detected an expansion of CD38<sup>+</sup> MDSCs in peripheral blood of advanced-stage cancer patients and validated targeting CD38 <i>in vivo</i> as a novel approach to cancer therapy. <i>Cancer Res; 75(19); 4074–85. ©2015 AACR</i>.</p></div>